# US 2010/0062996 A1 · Dioxolane derivates for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062996 A1
- Document ID: US20100062996A1
- Status: Published application
- Kind: A1
- Application number: 12/305,338
- Filed: 2006-12-07
- Published: 2010-03-11
- Earliest claimed: 2005-12-08
- Assignees: Clavis Pharma AS
- Inventors: Finn Myhren; Marit Liland Sandvold; Steinar Hagen; Ole Henrik Eriksen
- Web page: https://patentgrep.com/patent/US20100062996A1

## CPC

- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.

## Claims

### Claim 1

A compound having the following formula (I):
wherein:
R1 is
and R3 is selected from the group consisting of hydrogen, methyl, trifluoromethyl, fluorine, chlorine, bromine and iodine; and
X and Y can be either CH or a N atom with at least one of X or Y being N, and
Z and W are each independently Br, Cl, I, F, OR4 or NHR4 and at least one of Z and W is either OR4 or NHR4, and
R4 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
wherein m is a number from 0 to 2 and n is a number from 0 to 10,
R2 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
wherein m is a number from 0 to 2 and n is a number from 0 to 10, with the proviso that R2, R3 and R4 cannot simultaneously be hydrogen, or a
pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, defined as:
wherein R2 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) and R4 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
wherein m is a number from 0 to 2 and n is a number from 0 to 10, with the proviso that R2 and R4 cannot simultaneously be hydrogen, or a
pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1 defined as:
wherein R2 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) and R4 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
wherein m is a number from 0 to 2 and n is a number from 0 to 10, with the proviso that R2 and R4 cannot simultaneously be hydrogen, or a
pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1 selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim at position 5

-9. (canceled)

### Claim 10 (depends on 1)

A method for treating cancer in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A pharmaceutical preparation, comprising a compound of formula (I) as defined in claim 1, and a pharmaceutically acceptable excipient, diluent and/or carrier therefor.

### Claim 12 (depends on 10)

The method for treating cancer according to claim 10, wherein the cancer is a solid tumor.

### Claim 13 (depends on 10)

The method for treating cancer according to claim 10, wherein the cancer is a hematological cancer.

### Claim 14 (depends on 13)

The method for treating cancer according to claim 13, wherein the hematological cancer is selected from the group consisting of leukemias, lymphomas, and multiple myelomas.
